Bristol-Myers Squibb (0R1F) Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
0R1F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bristol-Myers Squibb Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$49.24 |
| 52 Week High | US$63.17 |
| 52 Week Low | US$42.54 |
| Beta | 0.31 |
| 1 Month Change | 15.59% |
| 3 Month Change | 4.86% |
| 1 Year Change | -16.86% |
| 3 Year Change | -39.13% |
| 5 Year Change | -20.50% |
| Change since IPO | -12.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R1F | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 5.8% | 0.6% | 2.3% |
| 1Y | -16.9% | 26.6% | 16.4% |
Return vs Industry: 0R1F underperformed the UK Pharmaceuticals industry which returned 26.9% over the past year.
Return vs Market: 0R1F underperformed the UK Market which returned 16.1% over the past year.
Price Volatility
| 0R1F volatility | |
|---|---|
| 0R1F Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R1F has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0R1F's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
| 0R1F fundamental statistics | |
|---|---|
| Market cap | US$100.16b |
| Earnings (TTM) | US$6.04b |
| Revenue (TTM) | US$48.03b |
Is 0R1F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R1F income statement (TTM) | |
|---|---|
| Revenue | US$48.03b |
| Cost of Revenue | US$12.90b |
| Gross Profit | US$35.14b |
| Other Expenses | US$29.10b |
| Earnings | US$6.04b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 05, 2026
| Earnings per share (EPS) | 2.97 |
| Gross Margin | 73.15% |
| Net Profit Margin | 12.57% |
| Debt/Equity Ratio | 263.3% |
How did 0R1F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/28 20:35 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bristol-Myers Squibb Company is covered by 44 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Luisa Hector | Berenberg |